- Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.
- However, the last changes she has brought to ARKG suggest caution in view of a market correction risk.
- In addition, she remains invested in high-growth names with the ETF providing exposure to the whole genomics ecosystem.
- Addition of cash-rich larger biotechs with significant COVID exposure to the portfolio is viewed as a strong positive.
- The target share price is in the $140-145 range, by the end of this year, with the possibility of a stock market correction, as per Cathie Wood herself.
For further details see:
ARKG: Precautionary Measures, But Transformational Objectives Remain Intact